We believe that DLBCL patients with IL‐6R‐positive, STAT3‐positive DLBCL that are wild type for SOCS1 and perhaps also produce IL‐6 should qualify to receive this antibody, ideally as a combination therapy with other targeted agents that are emerging from clinical trials. The gene discussed is IL6; the disease is diffuse large B-cell lymphoma.